JAMA Tx B.V., headquartered in Utrecht (NL), is a preclinical stage biotech venture emerging from the UMC Utrecht Department of Experimental Cardiology. Founded in 2025, the company builds on two decades of scientific expertise in extracellular-vesicle (EV) biology and gene-therapy translation for cardiovascular disease. Our mission is to enable the safe and precise delivery of proteins and programmable gene editors to the heart and other hard-to-reach tissues that current vectors cannot reach.

JAMA Tx

Org chart

Teams

Offices